HeraMED opens up new medtech markets with clinical study milestone
Health & Biotech
Health & Biotech
Link copied to
Special Report: ASX-listed HeraMED has completed a milestone clinical study ahead of schedule of its HeraBEAT pregnancy monitoring technology, taking another step towards tapping into the recent surge in digital transformation of maternity care.
HeraMED’s (ASX:HMD) study kicked off in July 2020 and was led by associate professor Paul Porter at Joondalup Health Campus in Australia. The purpose of the trial was to measure the usability, accuracy and reliability of the HeraBEAT foetal and maternal heart rate device, initially testing the device in the antenatal clinic then at the homes of 80 expectant mothers.
The research time is still crunching the data from the study and is expected to announce its results in the coming weeks.
While the data is still being analysed, the research team together with JHC decided to expand the study to include additional cases and explore further applications that could unlock new opportunities for HeraMED.
The successful trial represents much more to HeraMED than just clinical data. HeraMED has developed a strategy to generate clinical validation for its HeraCARE software-as-a-service and IoT platform for holistic, digital hybrid maternity care in order to establish the brand as the gold standard for remote, foetal and maternal wellbeing.
HeraMED said that by validating its technology in a clinical setting, the company can leverage these results to generate new commercial opportunities – specifically the fast-tracked adoption of digital health in maternity care following the advent of COVID-19, leading more expecting mothers to opt for in-home care.
HeraMED CEO and co-founder David Groberman said the data generated by the HeraBEAT study will provide that clinical validation that the company can leverage to crack into new markets.
“The study was conducted by a highly experienced clinical and research team that specialises in innovative technology focused on obstetrics and paediatrics,” said Groberman.
“We look forward to continuing to work with them to determine the potential for additional applications which may represent further value creation for HMD.
“We anticipate that the data generated from the study will provide important clinical validation of proprietary technology that we will leverage across our current as well as other markets to generate new opportunities.”
This article was developed in collaboration with HeraMED, a Stockhead advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.